Progression of impending central retinal vein occlusion to the ischemic variant following intravitreal bevacizumab

Korean J Ophthalmol. 2010 Jun;24(3):179-81. doi: 10.3341/kjo.2010.24.3.179. Epub 2010 Jun 5.


A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.

Keywords: Bevacizumab; Central retinal vein occlusion.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Disease Progression
  • Female
  • Fluorescein Angiography
  • Glaucoma, Neovascular / complications
  • Humans
  • Injections, Intraocular
  • Ischemia / diagnosis
  • Ischemia / etiology*
  • Ischemia / physiopathology
  • Middle Aged
  • Retinal Vein Occlusion / complications*
  • Retinal Vein Occlusion / drug therapy*
  • Retinal Vein Occlusion / physiopathology
  • Retinal Vessels*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / drug effects
  • Vitreous Body


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab